Founded in 2011 in the Netherlands, Zwiers Regulatory Consultancy (ZRC) accompanies start-ups and large players of the pharmaceutical industry throughout the entire lifecycle of their drugs and medical devices. The group offers its strategic and operational support from the initial clinical trial application to post-marketing compliance on a global scale.

Thanks to the renowned expertise of its team, the company has shown a 13% annual sales growth over the 2016-2022 period, with a significant acceleration over the past couple of years.

The acquisition will enable ProductLife Group (PLG) to:
• Expand its operational presence in the Netherlands, close to the European Medicines Agency (EMA);
• Strengthen its strategic expertise in the pre-marketing segment;
• Reinforce its presence among emerging biotech companies in Europe, complementary to its US-based activity.

Supported by 21 Invest France since 2019, PLG has completed 7 build-ups in total, in line with its initial strategic roadmap. Combined with strong organic growth, the group has thus tripled in size and now has 850 direct employees in 50 countries for a turnover of €M 80.

The refinancing carried out in parallel will allow PLG to pursue and further accelerate its international platform strategy. This new debt replaces the one put in place in July 2021 and also includes ESG commitments.

Xavier Duburcq, CEO of ProductLife Group, says: “With this acquisition, we are confident in PLG’s ability to support our clients in their complex development programs. This alliance will unlock meaningful potential and reinforce our ability to positively contribute to regulatory assessment, scientific progress, and launch of successful treatments.”

Fabrice Voituron, Managing Partner at 21 Invest France, adds: “This operation is a new illustration of the exceptional dynamics of PLG, which combines double-digit organic growth and ambitious external growth, all of this in a buoyant global market.”